https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-01 / G Ital Dermatol Venereol 2011 Apr;146(2):103-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-01 / G Ital Dermatol Venereol 2011 Apr;146(2):103-132011-04-01 00:00:002019-02-15 08:48:39Dendritic cells and cutaneous T-cell lymphomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-01 / Immunotherapy 2011 Apr;3(4):569-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-01 / Immunotherapy 2011 Apr;3(4):569-762011-04-01 00:00:002019-02-15 08:45:54Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-25 / Eur. J. Cell Biol. 2012 Jan;91(1):53-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-25 / Eur. J. Cell Biol. 2012 Jan;91(1):53-82011-03-25 00:00:002019-02-15 08:40:02Third generation dendritic cell vaccines for tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-02 / Cancer Immunol. Immunother. 2011 Jun;60(6):809-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-02 / Cancer Immunol. Immunother. 2011 Jun;60(6):809-182011-03-02 00:00:002019-02-15 08:40:07hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-332011-03-01 00:00:002019-02-15 08:49:20Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-19 / J. Neurooncol. 2011 Sep;104(3):659-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-19 / J. Neurooncol. 2011 Sep;104(3):659-672011-02-19 00:00:002019-02-15 08:46:14Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-10 / Gene Ther. 2011 Jun;18(6):584-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-10 / Gene Ther. 2011 Jun;18(6):584-932011-02-10 00:00:002019-02-15 08:49:19Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-506
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-5062011-02-09 00:00:002019-02-15 08:51:29IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-832011-02-03 00:00:002019-02-15 08:48:16Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells
